CN115427073A - 去优化SARS-CoV-2及其方法和用途 - Google Patents

去优化SARS-CoV-2及其方法和用途 Download PDF

Info

Publication number
CN115427073A
CN115427073A CN202180024216.XA CN202180024216A CN115427073A CN 115427073 A CN115427073 A CN 115427073A CN 202180024216 A CN202180024216 A CN 202180024216A CN 115427073 A CN115427073 A CN 115427073A
Authority
CN
China
Prior art keywords
cov
sars
coronavirus
polynucleotide
various embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180024216.XA
Other languages
English (en)
Chinese (zh)
Inventor
斯特芬·穆勒
约翰·罗伯特·科尔曼
王颖
杨晨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serum Institute of India Pvt Ltd
Kodak Jinnix Co ltd
Original Assignee
Serum Institute of India Pvt Ltd
Kodak Jinnix Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute of India Pvt Ltd, Kodak Jinnix Co ltd filed Critical Serum Institute of India Pvt Ltd
Publication of CN115427073A publication Critical patent/CN115427073A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
CN202180024216.XA 2020-01-28 2021-01-27 去优化SARS-CoV-2及其方法和用途 Pending CN115427073A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062966750P 2020-01-28 2020-01-28
US62/966,750 2020-01-28
US202063048942P 2020-07-07 2020-07-07
US63/048,942 2020-07-07
US202063079337P 2020-09-16 2020-09-16
US63/079,337 2020-09-16
US202063079853P 2020-09-17 2020-09-17
US63/079,853 2020-09-17
PCT/US2021/015246 WO2021154828A1 (fr) 2020-01-28 2021-01-27 Sars-cov-2 désoptimisé et ses procédés d'utilisation

Publications (1)

Publication Number Publication Date
CN115427073A true CN115427073A (zh) 2022-12-02

Family

ID=77078567

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180024216.XA Pending CN115427073A (zh) 2020-01-28 2021-01-27 去优化SARS-CoV-2及其方法和用途

Country Status (15)

Country Link
US (1) US20230117167A1 (fr)
EP (1) EP4096712A4 (fr)
JP (1) JP2023519640A (fr)
KR (1) KR20220132588A (fr)
CN (1) CN115427073A (fr)
AU (1) AU2021213121A1 (fr)
BR (1) BR112022014700A2 (fr)
CA (1) CA3168100A1 (fr)
CL (1) CL2022002030A1 (fr)
CO (1) CO2022010743A2 (fr)
IL (1) IL295112A (fr)
MX (1) MX2022009099A (fr)
PE (1) PE20230166A1 (fr)
TW (1) TW202144570A (fr)
WO (1) WO2021154828A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US20230108926A1 (en) * 2020-02-07 2023-04-06 RNAimmune, Inc. COMPOSITION AND METHOD OF mRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION
CN115803463A (zh) * 2020-03-06 2023-03-14 基因特力株式会社 用于诊断SARS-CoV-2的组合物、试剂盒以及通过使用所述试剂盒诊断SARS-CoV-2的方法
WO2022011428A1 (fr) * 2020-07-16 2022-01-20 Griffith University Vaccin contre un virus atténué vivant
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
WO2023037387A2 (fr) 2021-09-08 2023-03-16 Serum Institute Of India Private Limited Compositions de vaccin à combinaison virale lyophilisée et leur procédé de préparation
WO2023138770A1 (fr) * 2022-01-20 2023-07-27 Freie Universität Berlin Sars-cov-2 vivant atténué et vaccin fabriqué à partir de celui-ci
WO2023186946A1 (fr) * 2022-03-28 2023-10-05 Universität Bern Virus sars-cov-2 atténué à arrêt unique
WO2024052336A1 (fr) 2022-09-05 2024-03-14 Freie Universität Berlin Sars-cov-2 vivant atténué et vaccin fabriqué à partir de celui-ci
EP4331602A1 (fr) * 2022-09-05 2024-03-06 Freie Universität Berlin Sars-cov-2 vivant atténué et vaccin fabriqué à partir de celui-ci
WO2024079285A1 (fr) * 2022-10-12 2024-04-18 Universität Bern Traitement utilisant un virus du sars-cov-2 atténué un-avant-stop

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
EP2808384B1 (fr) * 2004-10-08 2017-12-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Modulation de la valeur d'adaptation réplicative par désoptimisation de codons synonymes
EP3431099B1 (fr) * 2007-03-30 2024-01-03 The Research Foundation for The State University of New York Virus attenues utiles pour des vaccins

Also Published As

Publication number Publication date
JP2023519640A (ja) 2023-05-11
MX2022009099A (es) 2022-10-20
TW202144570A (zh) 2021-12-01
KR20220132588A (ko) 2022-09-30
PE20230166A1 (es) 2023-02-01
CO2022010743A2 (es) 2022-08-30
WO2021154828A1 (fr) 2021-08-05
EP4096712A1 (fr) 2022-12-07
AU2021213121A1 (en) 2022-08-18
CA3168100A1 (fr) 2021-08-05
US20230117167A1 (en) 2023-04-20
EP4096712A4 (fr) 2024-05-08
IL295112A (en) 2022-09-01
BR112022014700A2 (pt) 2022-10-11
CL2022002030A1 (es) 2023-03-10

Similar Documents

Publication Publication Date Title
CN115427073A (zh) 去优化SARS-CoV-2及其方法和用途
JP2020031658A (ja) イヌにおける呼吸器疾患管理のための材料および方法
US8647637B2 (en) Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs
KR102472939B1 (ko) 페스티바이러스
JP5755265B2 (ja) 弱毒化ペスチウイルス
EP3394085B1 (fr) Vaccin contre le calicivirus félin
US20210401983A1 (en) Arthrogenic alphavirus vaccine
US20230181710A1 (en) Recombinant classical swine fever virus
KR20240047977A (ko) 탈최적화된 sars-cov-2 변이체 및 그의 방법 및 용도
JP2022507053A (ja) 新規ブタロタウイルス
KR20230005814A (ko) Cpg-어쥬번트된 sars-cov-2 바이러스 백신
RU2687150C2 (ru) Не встречающийся в природе вирус репродуктивно-респираторного синдрома свиней (bppcc) и способы применения
KR20230038205A (ko) 키메라 rsv 및 코로나바이러스 단백질, 면역원성 조성물, 및 사용 방법
EP2571519B1 (fr) Vaccin marqueur contre la peste porcine classique
Dunuwille MODULATION OF INFLAMMATORY CYTOKINE, CHEMOKINE, AND TOLL-LIKE RECEPTOR GENES AND TRANSCRIPTOME ANALYSIS OF EQUINE ENDOTHELIAL CELLS FOLLOWING INFECTION WITH EQUID HERPESVIRUS-1, AND EQUINE ARTERITIS VIRUS.
Alraddadi et al. Circulation of Non-MERS Coronaviruses in Imported Camels In Saudi Arabia
WO2018146257A1 (fr) Vaccin contre le virus de l'hépatite e

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination